MSD Manual

Please confirm that you are a health care professional

honeypot link

How To Aspirate or Inject an Olecranon Bursa

By

Alexandra Villa-Forte

, MD, MPH, Cleveland Clinic

Reviewed/Revised Apr 2023
View PATIENT EDUCATION
Topic Resources

Aspiration of the olecranon bursa is done for diagnostic purposes (eg, to diagnose septic bursitis, gout). Injection of corticosteroids into the olecranon bursa is typically avoided but may be done selectively (eg, in patients with recurrent and painful, large effusions).

The olecranon bursa lies immediately below the skin. This superficial location increases the risk of skin damage, fluid leakage, and infection from corticosteroid injection. Thus, injection of corticosteroids is usually avoided for superficial bursae. Occasionally, corticosteroid injection is used to treat refractory or painful bursitis due to crystals (eg, gout Gout Gout is a disorder caused by hyperuricemia (serum urate > 6.8 mg/dL [> 0.4 mmol/L]) that results in the precipitation of monosodium urate crystals in and around joints, most often causing recurrent... read more Gout ) or rheumatoid arthritis Rheumatoid Arthritis (RA) Rheumatoid arthritis is a chronic systemic autoimmune disease that primarily involves the joints. Rheumatoid arthritis causes damage mediated by cytokines, chemokines, and metalloproteases.... read more Rheumatoid Arthritis (RA) , or if there is a significant recurrent noninfectious post-traumatic bursal effusion.

Indications for Aspirating or Injecting an Olecranon Bursa

  • Aspiration of bursal effusion to determine cause of bursitis

  • Rarely, injection of corticosteroid for persistent or recurrent bursitis

Olecranon bursa aspiration is usually done for diagnosis (eg, to diagnose septic or crystal-induced bursitis). Because the olecranon bursa is the most common site of septic bursitis, olecranon effusion should be sent to the laboratory for cell count and differential, crystal analysis, Gram stain, culture, and sensitivity tests.

Corticosteroid injection is occasionally necessary in the olecranon bursa. Therapeutic injection should be done only if all of the following criteria are satisfied:

  • Infection has been excluded by bursal fluid analysis.

  • Bursal fluid reaccumulates.

  • Symptoms are not relieved by local measures such as ice, elevation, elastic bandage or orthosis wear, and nonsteroidal anti-inflammatory drugs (if not contraindicated).

When needed, bursal injection may provide rapid relief, which can be particularly beneficial for large or painful effusions.

Contraindications to Aspirating or Injecting an Olecranon Bursa

Absolute contraindications

  • Hypersensitivity to an injected substance

  • For corticosteroid injection, suspected septic bursitis

Insertion of a needle directly through infected skin should be avoided; however, if there is clinical suspicion for septic bursitis, the bursa should be aspirated, ideally before giving systemic antibiotics.

Relative contraindications

  • Poorly controlled diabetes: Any benefit of corticosteroids is weighed against risk of worsening glycemic control and risk of infection.

  • Recent (ie, within the last 3 months) corticosteroid injection into same site (although no evidence has evaluated this practice)

Complications of Aspirating or Injecting an Olecranon Bursa

Complications are uncommon and include

  • Subcutaneous fat atrophy, skin atrophy and sinus tracts, temporary skin depigmentation, and infection due to superficial (< 0.5 cm deep) corticosteroid injection

  • Painful local reaction thought to result from a chemical synovitis in response to the crystals in the corticosteroid solution (sometimes called postinjection flare) occurring within a few hours of depot corticosteroid injection and usually lasting ≤ 48 hours

  • In diabetic patients, hyperglycemia after a depot corticosteroid injection

Equipment for Aspirating or Injecting an Olecranon Bursa

  • Antiseptic solution (eg, chlorhexidine, povidone iodine, isopropyl alcohol)

  • Sterile gauze, gloves, adhesive bandage

  • 20-mL syringe with 18- to 20-gauge needle for fluid withdrawal

  • Needle insertion site anesthesia (eg, topical freezing spray and/or injectable 1% lidocaine without epinephrine, in a 3-mL syringe)

  • Optional: For therapeutic injection, 5- to 10-mL syringe with 2 to 3 mL 1% lidocaine (without epinephrine) mixed with injectable depot corticosteroid (eg, triamcinolone acetonide, 20 mg)

  • Hemostat, if switching of syringe while leaving the needle inserted after aspiration is anticipated

  • Some 3-, 5-, and 10-mL syringes

  • For diagnostic aspiration, appropriate tubes for specimen collection, including blood culture bottles

Having an assistant is helpful.

Additional Considerations for Aspirating or Injecting an Olecranon Bursa

  • For bursal injection, local anesthetic and depot corticosteroid can be mixed in a single syringe. Adding the anesthetic helps confirm good needle placement when injection immediately relieves pain. Adding anesthetic also may decrease the risk of the corticosteroid causing subcutaneous fat atrophy and the risk of postinjection flare.

  • Corticosteroid injection is rarely necessary in the olecranon bursa (based on an increased risk of infection and skin atrophy and a paucity of data showing improved long-term outcomes).

  • Septic bursitis cannot be ruled out by the initial gross and microscopic examination of the aspirated effusion; infected fluids (even from Staphylococcus aureus, the most common organism) tend to show a minimal fluid leukocytosis (although there is generally a high percentage of neutrophils). If the history or physical examination suggests septic bursitis, withhold corticosteroid injection. Septic bursitis requires drainage or sometimes bursal excision in addition to systemic antibiotics.

  • Surgical excision of the bursa may be necessary for recalcitrant or recurrent sterile effusions or unresolving infections.

Relevant Anatomy for Aspirating or Injecting an Olecranon Bursa

  • The olecranon bursa overlies the tip of the olecranon process and is superficial.

Positioning for Aspirating or Injecting an Olecranon Bursa

  • Seat or partially recline the patient, with the arm comfortably flexed about 90° at the elbow and resting on a bedside table. The patient may also be supine on an examination table with the elbow flexed.

  • To avoid vasovagal episodes, avert the patient's head and orient your work area so that the patient does not see the needles.

Step-by-Step Description of Aspirating or Injecting an Olecranon Bursa

Prepare the site

  • Identify the bursa's point of maximum fullness and aspirate at the base (bottom) of the distended bursa, trying to avoid areas of skin thinning to limit likelihood of post-aspiration leakage.

  • Prepare the area with antiseptic solution.

  • Spray freezing solution at the needle insertion site until it just blanches and/or inject a skin wheal of local anesthetic (eg, ≤ 1 mL).

Puncture the bursa

Aftercare for Aspirating or Injecting an Olecranon Bursa

  • A protective elastic elbow brace or compression bandage may prevent reaccumulation of fluid.

  • Prescribe limited activity, ice, elevation, and, if not contraindicated, oral nonsteroidal anti-inflammatory drugs (NSAIDs) until pain subsides.

  • Instruct the patient to return for reassessment to exclude infection if pain is continuously and progressively increasing after several hours or persists for > 48 hours.

Warnings and Common Errors for Aspirating or Injecting an Olecranon Bursa

  • Do not inject corticosteroids against resistance; if there is resistance, slightly withdraw the needle.

Tips and Tricks for Aspirating or Injecting an Olecranon Bursa

  • Consider doing ultrasonography if there is no obvious large effusion.

  • When inspecting bursal fluid, consider the following: The blood due to a traumatic needle insertion tends to be nonuniformly bloody and tends to clot. Nontraumatic fluid should be evaluated by polarized light microscopy for the presence of crystals.

Reference

  • 1. Yui JC, Preskill C, Greenlund LS: Arthrocentesis and joint injection in patients receiving direct oral anticoagulants. Mayo Clin Proc 92(8):1223–1226, 2017. doi: 10.1016/j.mayocp.2017.04.007

View PATIENT EDUCATION
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz! 
iOS ANDROID
iOS ANDROID
iOS ANDROID
TOP